Bayer’s Kidney Disease Drug Disappoints On Cutting Cardiovascular Death
Bayer AG (OTC:BAYRY) reported disappointing results from its approved med Kerendia (finerenone) didn’t reach significance on all-cause mortality in a pooled…
Philips Recalls Some Ventilators Over Contaminated Plastic Component
The FDA is alerting patients, caregivers, and health care providers that Koninklijke Philips NV (NYSE:PHG) Respironics recalled certain bi-level positive airway pressure…
TRACON Secures FDA Nod For Early-Stage Study In Soft-Tissue Cancer
The FDA has signed off TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) initiation of a Phase 1/2 trial of YH001 in combination with envafolimab…
Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) announced results from a Phase 2 study of cemdisiran for immunoglobulin A nephropathy (IgAN). Cemdisiran is an…
Switzerland Approves First Next-Generation Bivalent COVID-19 Booster Vaccine
Switzerland’s regulatory authority has granted conditional approval for Moderna Inc’s (NASDAQ:MRNA) omicron-targeting bivalent booster vaccine for adults 18 years and older. Spikevax…
BeyondSpring Presents New Data From Lead Asset On Neutropenia In Multiple Myeloma Patients
BeyondSpring Inc (NASDAQ:BYSI) announced new data from a study evaluating the reduction in neutropenia burden with lead asset plinabulin in combination…
BrainsWay’s Stimulation Device Scores FDA Approval For Depression Settings
The FDA has granted 510(k) clearance to BrainsWay Ltd’s (NASDAQ:BWAY) Deep Transcranial Magnetic Stimulation (TMS) H7 Coil for its use in treating…
IDEAYA Achieves First Milestone In GSK Pact For Pol Theta Helicase Inhibitor Candidate
IDEAYA Biosciences Inc (NASDAQ:IDYA) has achieved a preclinical development milestone in connection with ongoing IND-enabling studies for its Pol Theta Helicase…
Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial
Additional readouts from Valneva SE’s (NASDAQ:VALN) pivotal VLA2001-301 “Cov-Compare” trial of COVID-19 vaccine VLA2001 showed persistent and first positive heterologous booster…
Amgen’s Repatha Shows Long Term Lowering Of Bad Cholesterol, Tolerance
Amgen Inc (NASDAQ:AMGN) presented new data from the Phase 3 FOURIER open-label extension (OLE) studies of Repatha (evolocumab) in adults with…